All Oncology News

Maurie Markman, MD, discusses the role of decision support tools in cancer management.

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

The FDA has expanded the indications of 2 assays to identify patients with HER2+ breast cancer for treatment with T-DXd.

Muzastotug has been granted fast track designation by the FDA for use in combination with pembrolizumab as treatment for patients with MSS mCRC.

Proton beam therapies can result in strong outcomes for patients with throat cancer according to Mayo Clinic researchers.

Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

Researchers at UCSF share results about individualized breast cancer screenings from the WISDOM study.

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

Dual-antibody, off-the-shelf therapy showed deep durable responses in patients with extra medullary multiple myeloma according to Mayo Clinic researchers.

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.